SAN DIEGO, Sept. 1, 2016 /PRNewswire/ -- Mast
Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company
developing novel, clinical-stage therapies for sickle cell disease
and heart failure, today announced that the Company's Chief
Executive Officer, Brian M. Culley,
will present at the 18th Annual Rodman & Renshaw
Global Investment Conference on Tuesday,
September 13, 2016 at 11:40 a.m.
Eastern time in the Kennedy II Salon at the Lotte New York
Palace hotel in New York City.
Interested parties can access a live audio webcast on the Mast
Therapeutics web site at www.masttherapeutics.com. An archived
presentation will be available on the web site for 30 days.
About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical
company headquartered in San Diego,
California. The Company is developing two clinical-stage
investigational new drugs for serious or life-threatening diseases
and conditions. Vepoloxamer, the Company's lead product candidate,
is in Phase 3 clinical development for the treatment of
vaso-occlusive crisis in patients with sickle cell disease and in
Phase 2 clinical development for the treatment of patients with
heart failure. Enrollment in the Company's 388-patient Phase
3 study of vepoloxamer in patients with sickle cell disease, known
as the EPIC study, was completed earlier this year.
Enrollment in the Company's Phase 2 study of vepoloxamer in
patients with chronic heart failure is ongoing. AIR001, the
Company's second product candidate, is in Phase 2 clinical
development for the treatment of patients with heart failure with
preserved ejection fraction (HFpEF). Enrollment in Phase 2 studies
of AIR001 in patients with HFpEF are ongoing, including a
100-patient, multicenter, randomized, double-blind,
placebo-controlled, Phase 2 study in patients with HFpEF being
conducted by the Heart Failure Clinical Research Network.
More information can be found on the Company's web site at
www.masttherapeutics.com. (Twitter: @MastThera)
Mast Therapeutics™ and the corporate logo are trademarks of Mast
Therapeutics, Inc.
Logo -
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mast-therapeutics-to-present-at-18th-annual-rodman--renshaw-global-investment-conference-on-september-13th-300320282.html
SOURCE Mast Therapeutics